Chinese regulators approved the drug for the same subset of advanced, previously treated EGFR-mutated NSCLC patients in 2023.

Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.

With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving beyond cancer and rare disease.

The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.

The gene therapy for an undisclosed central nervous system disease is based on JCR's delivery technology and Modalis' epigenome editing platform.

The grants, awarded in partnership with the Authority of Social Contribution-Ma'an, will fund 11 research projects across multiple disease areas.

Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.

Innovent has submitted a second new drug application (NDA) to China's National Medical Products Administration (NMPA) seeking approval for Dovbleron as a treatment for ROS1-positive advanced NSCLC ...

The firm also announced that it was divesting most of its equity interest in Shanghai Hutchison Pharmaceuticals to invest in its own pipeline.

The Congressional Budget Office said policies to increase treatment uptake could affect Medicaid, Social Security, and other government programs.

Regulators approved the first bespoke cell therapies for solid tumors this year, while drugmakers expanded and improved upon ...

The decision follows a similar one in the US and is due to the drug's failure to significantly improve overall survival versus chemo in the TROPION-Lung01 trial.